Intercept Pharmaceuticals Competitors, Revenue, Alternatives and Pricing
Overview
Employee Data
- Intercept Pharmaceuticals has 686 Employees.
- Intercept Pharmaceuticals currently has 1 job openings.
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
Advertise Here | ||||||
#1 | N/A | 686 | N/A | N/A | - | N/A |
#2 | $372.5M | 1853 | N/A | N/A | - | N/A |
#3 | $38.2M | 190 | N/A | N/A | - | N/A |
#4 | N/A | 36 | N/A | N/A | - | N/A |
#5 | $22.1M | 110 | 24% | N/A | - | N/A |
#6 | $581.3M | 2892 | N/A | N/A | - | N/A |
#7 | $13.5M | 67 | N/A | N/A | - | N/A |
#8 | $43.4M | 216 | N/A | N/A | - | N/A |
#9 | $15.1M | 75 | 10% | N/A | - | N/A |
#10 | $47.4M | 236 | 15% | N/A | 4.2/5 | N/A |
What Is Intercept Pharmaceuticals?
New York City-based Intercept Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases. Since 2002, Intercept researchers have published extensively on the key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver with preclinical data from numerous studies providing strong rationale for the advancement of FXR agonists as hepatoprotective therapeutics in chronic liver disease. The company intends to lead in the advancement of drug candidates acting on FXR and other bile acid receptors and is developing a pipeline of novel lead compounds for multiple indications.
keywords:N/A686
Number of Employees
N/A
Revenue (est)
1
Current Jobs
N/A
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
N/A
Type
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
#1 | $221.6M | 686 | N/A | N/A | - | N/A |
#2 | $140.6M | 686 | N/A | N/A | - | N/A |
#3 | $144.5M | 688 | N/A | N/A | - | N/A |
#4 | $124.9M | 694 | N/A | N/A | - | N/A |
#5 | $157.5M | 694 | N/A | N/A | - | N/A |